KEY FACTS {#cesec1}
=========

Etiology {#cesec2}
--------

•Viral illness transmitted by respiratory droplets

Clinical Issues {#cesec3}
---------------

•8,000 cases and 744 deaths (2002-2003 outbreak)•Presentation: Fever, headache, and myalgias, followed by nonproductive cough, dyspnea, and radiographically confirmed pneumonia•Labs: Serology, RT-PCR, viral isolation•Supportive therapy: Antipyretics, oxygen, ventilation•Overall fatality 10% (\> 50% in persons older than 60)

Microscopic Pathology {#cesec4}
---------------------

•Acute exudative DAD: Edema, hyaline membranes, alveolar collapse, desquamation of alveolar epithelial cells, and fibrous tissue in alveolar space•After 10-14 days: Interstitial/airspace fibrosis and pneumocyte hyperplasia•Ancillary tests: IHC (alveolar epithelial cells and macrophages), ISH, and EM

 {#cesec5}

Terminology {#cesec6}
-----------

### Definitions {#cesec7}

•Latin: "corona" (crown, halo), as in surface projections on EM: Coronaviridae family

Etiology/Pathogenesis {#cesec8}
---------------------

### Infectious Agents {#cesec9}

•Viral illness transmitted by respiratory droplets•Virus infects tracheobronchial and alveolar epithelial cells and immune cells; binds host receptor angiotensin-converting enzyme 2 (ACE2)•Symptoms due to direct viral cytopathic effects, including apoptosis, hyperinduction of chemokines and cytokines, insufficient interferon reaction, and compromised cellular immune response•Incubation period: 2-10 days•Contagious period: Start of symptoms until 10 days after resolution

Clinical Issues {#cesec10}
---------------

### Epidemiology {#cesec11}

•2002-2003 outbreak originating in Asia resulted in \> 8,000 cases and 744 deaths in 29 countries worldwide•No cases reported since 2004

### Site {#cesec12}

•Lungs

### Presentation {#cesec13}

•Early symptoms of fever, headache, and myalgias•Days 2-7: Nonproductive cough and dyspnea•Day 7-10: Radiographically confirmed pneumonia

### Laboratory Tests {#cesec14}

•CBC: Lymphopenia (70-90%)•Serology: Enzyme immunoassay (EIA)•RT-PCR (respiratory samples, stool, plasma, serum)

### Treatment {#cesec15}

•Supportive (antipyretics, oxygen, ventilation)•Isolation in negative pressure rooms

### Prognosis {#cesec16}

•Overall fatality: 10% (\> 50% in persons older than 60)

Image Findings {#cesec17}
--------------

### Radiographic Findings {#cesec18}

•Nonspecific: Normal at presentation (20%), focal opacity in peripheral middle and lower lung zones (40%), multifocal opacities/consolidations (27%), or diffuse consolidation (14%)

Microbiology {#cesec19}
------------

### Virus Features {#cesec20}

•Enveloped, single-strand RNA virus•80-90 nm in size, helical nucleocapsid•29,727 nucleotides (13 genes; 14 proteins)

### Culture {#cesec21}

•Grows in Vero-E6 cells (requires BSL-3 facility)

Microscopic Pathology {#cesec22}
---------------------

### Histologic Features {#cesec23}

•Lungs○Acute exudative diffuse alveolar damage (DAD): Edema, hyaline membranes, alveolar collapse, desquamation of alveolar epithelial cells, and fibrous tissue in alveolar space○After 10-14 days: Interstitial/airspace fibrosis and pneumocyte hyperplasia

Ancillary Tests {#cesec24}
---------------

### Immunohistochemistry {#cesec25}

•Staining of alveolar epithelial cells and macrophages using anti-SARS-associated coronavirus (SARS-CoV) antibodies

### In Situ Hybridization {#cesec26}

•Staining of pneumocytes, lymphocytes, and macrophages

### Electron Microscopy {#cesec27}

•Coronaviruses with large granular cytoplasmic areas, nucleocapsid inclusions, and typical double-membrane vesicles

Differential Diagnosis {#cesec28}
----------------------

### Other Causes of Severe Respiratory Disease/DAD {#cesec29}

•Viral pneumonia (other coronaviruses, influenza A or B, respiratory syncytial virus, cytomegalovirus, herpes simplex virus, Middle Eastern respiratory syndrome)○Negative SARS-CoV serology, viral proteins, or nucleic acids &/or positive serology for other agents•*Mycoplasma pneumoniae* pneumonia, *Mycobacterium avium* complex pneumonia, cryptococcal pneumonia, sepsis○Positive Gram, MSS, or AFB stains•Noninfectious complications of transplantation, connective tissue diseases, acute exacerbation of idiopathic pulmonary fibrosis, drugs, radiation therapy, acute interstitial pneumonia○Low clinical suspicion for SARS, negative SARS-CoV serology, viral proteins or nucleic acids•Acute interstitial pneumonia○No known cause

Diagnostic Checklist {#cesec30}
--------------------

### CDC Guidelines {#cesec31}

•Radiologically confirmed pneumonia or acute respiratory distress syndrome of unknown etiology○With travel to southern China, Hong Kong, Taiwan &/or employment exposure to SARS-CoV in 10 days before illness onset○Or unexplained cluster of cases of atypical pneumonia without an alternative diagnosis

SARS-CoV infections exhibit findings consistent with acute exudate diffuse alveolar damage, a pattern of lung damage associated with many infectious and noninfectious etiologies.

This CXR shows diffuse bilateral ground-glass opacities ![](white-solid-9780323376778.gif) in a patient with SARS. Focal lower lung opacities are the most common finding, but radiographs are normal in 20% of symptomatic patients.(From DI2: Chest.)

Diffuse alveolar damage is characterized by edema, desquamation of alveolar epithelial cells, hyaline membranes, alveolar collapse, and fibrous tissue in alveolar space.

Hyaline membranes ![](black-open-9780323376778.gif) are a prominent feature of diffuse alveolar damage, seen in SARS-CoV infection.

As diffuse alveolar damage begins to organize over a period of days, the alveolar spaces are variably filled with edema, macrophages, and fibroblasts.
